September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
May 2018 in “Dermatologic Surgery”
1 citations
,
April 2019 in “Journal of Investigative Dermatology” VB1953 gel significantly reduced acne and resistant bacteria in patients who didn't respond to clindamycin.
November 2005 in “Reactions Weekly” A man treated with gefitinib for lung cancer grew new hair on his bald scalp.
January 2025 in “International Journal of Molecular Sciences” Fenugreek extract may help treat benign prostatic hyperplasia.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
EFBL offers hidden incisions, faster recovery, and fewer risks, but may raise hairline and cost more.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
Brazilian keratin treatment can cause skin reactions like eczema.
Brunsting-Perry pemphigoid can cause scarring hair loss and may be underdiagnosed.
September 2024 in “BMJ Case Reports” An adult had a rare scalp infection in the forehead area, treated successfully with itraconazole.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
July 2009 in “Guoji yiyao weisheng daobao” Combining α1A-blockers with Prozac is more effective for treating premature ejaculation than Prozac alone.
10 citations
,
April 2018 in “Facial Plastic Surgery” The surgical technique of scalp advancement and pretrichial brow lift shortens the forehead and lifts brows, is good for women and transgender women with high foreheads, but not recommended for men and has some risks.
January 2026 in “Journal of Ayurveda and Integrated Medical Sciences” Bhringaraj extract tablets significantly reduce hair fall and are well-tolerated.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
The TrichoConcept™ line is effective for personalized hair loss treatments.
3 citations
,
November 2020 in “Clinical, Cosmetic and Investigational Dermatology” Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
9 citations
,
July 2019 in “Dermatologic therapy” Alitretinoin can effectively treat frontal fibrosing alopecia.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
April 2013 in “Developmental Cell” Brg1 is crucial for keeping hair follicle stem cells and repairing skin, working with the Sonic Hedgehog pathway to promote hair growth.
November 2019 in “British Journal of Dermatology” FOL-005 peptide may help treat excessive hair growth safely.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.